Enhanced Anticancer Potential of Combined Genistein and Dexamethasone Treatment in Melanoma
Journal of Experimental Pharmacology and Toxicology · 07.05.2026 · 3 (1) · 1
DOI: 10.64253/032025jept001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Pharmacology and Toxicology, online erschienen am 07.05.2026. Verfasst von Andra Tiberia Păcurar und 2 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Advanced malignant melanoma continues to be a highly invasive type of cancer with an unfavorable prognosis and limited therapeutic outcomes.
Methods
The current study investigated the cytotoxic potential and morphological effects of genistein (GEN) and dexamethasone (DEX), administered individually and in combination, on murine melanoma cells B164A5, using normal epidermal cells JB6 Cl 41-5a as controls.
Results
Treatment with GEN induced a dose-dependent decrease in the viability of melanoma cells, reaching 60.52% at 50 µM, in accordance with its known capacity to both inhibit proliferation and induce apoptosis by modulating NF-κB and Akt signaling pathways. DEX demonstrated moderate cytotoxic activity (71.34% viability at 50 µM), mirroring its recognized adjuvant role in cancer therapy. Combined treatment with both GEN (25 µM) and DEX (50 µM) resulted in the highest cytotoxicity (48.97% viability), suggesting a synergistic effect likely mediated by augmented apoptotic signaling and oxidative stress. The MTT assay and morphological analyses confirmed apoptotic characteristics, including cell contraction and detachment, while normal cells remained over 90% viable.
Conclusions
These results show that GEN, especially when combined with DEX, has selective cytotoxicity against melanoma cells and may serve as a potentially promising adjuvant candidate for future pharmacological strategies targeting malignant melanoma.
Zitieren
APA
Păcurar, A. T., Smeu, A., & Marcovici, I. (2026). Enhanced Anticancer Potential of Combined Genistein and Dexamethasone Treatment in Melanoma. Journal of Experimental Pharmacology and Toxicology, 3(1), 1. https://doi.org/10.64253/032025jept001
Vancouver
Păcurar AT, Smeu A, Marcovici I. Enhanced Anticancer Potential of Combined Genistein and Dexamethasone Treatment in Melanoma. Journal of Experimental Pharmacology and Toxicology. 2026;3(1):1. doi:10.64253/032025jept001
BibTeX
@article{Pcurar2026,
author = {Păcurar, Andra Tiberia and Smeu, Andreea and Marcovici, Iasmina},
title = {Enhanced Anticancer Potential of Combined Genistein and Dexamethasone Treatment in Melanoma},
journal = {Journal of Experimental Pharmacology and Toxicology},
year = {2026},
volume = {3},
number = {1},
pages = {1},
doi = {10.64253/032025jept001}
}
EUVIMED